AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04261179
Drug: Lymphoseek
RxNorm normalized name: Lymphoseek
DrugBank: Tilmanocept (DB15373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg microgram(s), timepoint: 30-60 minutes
Trial: NCT01046045
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
Trial: NCT01225822
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
Trial: NCT01225822
Drug: BIBR 1048
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
Trial: NCT03959852
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
Trial: NCT00894504
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Trial: NCT00894504
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Trial: NCT00894504
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
Trial: NCT01225822
Drug: BIBR 1048
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
Trial: NCT01225822
Drug: BIBR 1048
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
Trial: NCT01225822
Drug: BIBR 1048
RxNorm normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg q.d BIBR 1048 capsule for 5-10 treatment period
Trial: NCT00164710
Drug: sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00164710
Drug: amodiaquine plus sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00164710
Drug: amodiaquine plus artesunate
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00164710
Drug: chlorproguanil-dapsone plus artesunate
RxNorm normalized name: Artesunate
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00770588
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
Trial: NCT00080990
Drug: alvocidib
RxNorm normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00080990
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00504283
Drug: Toradol
RxNorm normalized name: Toradol
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00504283
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04657562
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.
Trial: NCT00157898
Drug: Comparator: ceftriaxone + metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02872012
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine applied to the non-cryoanesthesia eye.
Trial: NCT00672282
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg p.o. daily
Trial: NCT00219245
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01390441
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Trial: NCT01390441
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
Trial: NCT01079143
Drug: Neoral
RxNorm normalized name: Neoral
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
Trial: NCT00440245
Drug: salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 micrograms salbutamol from MDI
Trial: NCT01079143
Drug: Myfortic
RxNorm normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days.
Trial: NCT05240274
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 500mg OD for 3 months to start within 10 days post-renal transplant
Trial: NCT02001909
Drug: Regorafenib (Stivarga, BAY73-4506)
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
Trial: NCT02001909
Drug: Neomycin
RxNorm normalized name: Neomycin
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
Trial: NCT00887029
Drug: DuoTrav (travoprost-timolol ophthalmic drops)
RxNorm normalized name: TRAVOPROST COMPONENT OF DUOTRAV
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: topical ophthalmic drops instilled 1 drop daily
Trial: NCT00887029
Drug: Xalacom (latanoprost-timolol ophthalmic drops)
RxNorm normalized name: latanoprost / timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical ophthalmic drops instilled 1 drop daily
Trial: NCT03497715
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Test 1
Trial: NCT00732992
Drug: Sunitinib, Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
Trial: NCT00004072
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
Trial: NCT00004072
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
Trial: NCT02491892
Drug: Pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
Trial: NCT00073437
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03959592
Drug: Lutein, zeaxanthin and mesozeaxanthin
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
Trial: NCT00377988
Drug: Transdermal Contraceptive System
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
Trial: NCT00377988
Drug: Norgestimate-containing oral contraceptives with EE
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
Trial: NCT04426435
Drug: honey based (HB) syrup
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: honey-based syrup is prepared according to the documented Persian Medicine manuscripts with some modifications. HB is a mixture of honey, rose water and saffron. Each 100g of HB consisted of 79.87 g honey, 19.97 g rose water, and 0.16 g saffron.~All the ingredients were licensed and approved by The Islamic Republic of Iran Food and Drug Organization (I.R.I.FDO).
Trial: NCT03482362
Drug: Vinorelbine Tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
Trial: NCT02669615
Drug: Melphalan HCl for injection (propylene glycol free)
RxNorm normalized name: MELPHALAN HYDROCHLORIDE
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During the study period, patients will receive 200 mg/m\^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
Trial: NCT00823836
Drug: ropinirole PR/XR
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Trial: NCT00823836
Drug: ropinirole IR
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period.
Trial: NCT01895036
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01971281
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m\^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
Trial: NCT01971281
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m\^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
Trial: NCT00175747
Drug: Inhaled Budesonide 800 µg twice daily
RxNorm normalized name: Budesonide Inhalation Suspension
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00884897
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin given as 20 IU BID
Trial: NCT01602510
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
Trial: NCT01151215
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, od
Trial: NCT00160277
Drug: Moxonidine
RxNorm normalized name: moxonidine
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00246935
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00064142
Drug: halofuginone hydrobromide
RxNorm normalized name: Halofuginone hydrobromide
DrugBank: Halofuginone (DB04866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT00453102
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
Trial: NCT00453102
Drug: Ibritumomab Tiuxetan
RxNorm normalized name: ibritumomab tiuxetan
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
Trial: NCT03051659
Drug: Eribulin Mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
Trial: NCT00304772
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg/day
Trial: NCT03051659
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
Trial: NCT00304772
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg/day
Trial: NCT04258657
Drug: paclitaxel-albumin and S-1
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: neoadjuvant chomotherapy with paclitaxel-albumin and S-1 for advanced gastric cancer
Trial: NCT01320878
Drug: iloprost nebuliser solution
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
Trial: NCT01320878
Drug: iloprost nebuliser solution
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
Trial: NCT01320878
Drug: distilled water
RxNorm normalized name: Distilled Water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: distilled water 2 ml per session
Trial: NCT02401971
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT01214421
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets of 15 or 30 mg
Trial: NCT04565262
Drug: NAs+IFN-α
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAs+IFN-α:(NAs +IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96 weeks。 NAs+(NAs+IFN-α) :NAs/48weeks+(NAs+ IFN)/96 weeks：NAs（when the CHB patients\<2years old, the drug is LAM）for 48 weeks ，then combined with IFN-α（when the CHB patients\<3years old, the drug is IFN-α）for 96weeks。 Response guided treatment（RGT） by HBsAg quantification： The course of interferon alpha was 24 weeks after HBsAg and HBeAg turned negative up to 96 weeks, and NAs was discontinued 12 months after HBsAg serological conversion.
Trial: NCT03535051
Drug: Tacrolimus Oint 0.03%
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical daily tacrolimus ointment application
Trial: NCT00585078
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04362137
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 5 mg tablets
Trial: NCT03465943
Drug: Ringer
RxNorm normalized name: RINGER'S
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1L of Ringer's solution as a preload in one group.
Trial: NCT03465943
Drug: Voluven
RxNorm normalized name: Voluven
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
Trial: NCT00983112
Drug: Human Fibrinogen and human thrombin (Evicel)
RxNorm normalized name: fibrinogen, human / thrombin, human Prefilled Syringe
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product to be applied intraoperatively. No further administration will take place after this.
Trial: NCT00983112
Drug: Sodium Chlorure (Physiological saline)
RxNorm normalized name: sodium chlorate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sterile concentration, local use.
Trial: NCT00844597
Drug: AVI-4658 for Injection
RxNorm normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
Trial: NCT01779453
Drug: ETC-1002
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
Trial: NCT01779453
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10mg once daily for 8 weeks